These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 28673739)

  • 1. Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism.
    Gleave JA; Arathoon LR; Trinh D; Lizal KE; Giguère N; Barber JHM; Najarali Z; Khan MH; Thiele SL; Semmen MS; Koprich JB; Brotchie JM; Eubanks JH; Trudeau LE; Nash JE
    Neurobiol Dis; 2017 Oct; 106():133-146. PubMed ID: 28673739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirt3 protects dopaminergic neurons from mitochondrial oxidative stress.
    Shi H; Deng HX; Gius D; Schumacker PT; Surmeier DJ; Ma YC
    Hum Mol Genet; 2017 May; 26(10):1915-1926. PubMed ID: 28369333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway.
    Park JH; Burgess JD; Faroqi AH; DeMeo NN; Fiesel FC; Springer W; Delenclos M; McLean PJ
    Mol Neurodegener; 2020 Jan; 15(1):5. PubMed ID: 31931835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe nigrostriatal degeneration without clinical parkinsonism in patients with polymerase gamma mutations.
    Tzoulis C; Tran GT; Schwarzlmüller T; Specht K; Haugarvoll K; Balafkan N; Lilleng PK; Miletic H; Biermann M; Bindoff LA
    Brain; 2013 Aug; 136(Pt 8):2393-404. PubMed ID: 23625061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons.
    Caudal D; Alvarsson A; Björklund A; Svenningsson P
    Exp Neurol; 2015 Nov; 273():243-52. PubMed ID: 26363495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-striatal infusion of the small molecule alpha-synuclein aggregator, FN075, does not enhance parkinsonism in a subclinical AAV-alpha-synuclein rat model.
    Patton T; Comini G; Narasimhan K; Cairns AG; Ådén J; Almqvist F; Bemelmans A; Brouillet E; McKernan DP; Dowd E
    Eur J Neurosci; 2024 Sep; 60(6):5234-5248. PubMed ID: 39143728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein.
    Ciron C; Zheng L; Bobela W; Knott GW; Leone TC; Kelly DP; Schneider BL
    Acta Neuropathol Commun; 2015 Apr; 3():16. PubMed ID: 25853296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct detection of alpha synuclein oligomers in vivo.
    Dimant H; Kalia SK; Kalia LV; Zhu LN; Kibuuka L; Ebrahimi-Fakhari D; McFarland NR; Fan Z; Hyman BT; McLean PJ
    Acta Neuropathol Commun; 2013 May; 1():6. PubMed ID: 24252244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melatonin prevents dopaminergic cell loss induced by lentiviral vectors expressing A30P mutant alpha-synuclein.
    Brito-Armas JM; Baekelandt V; Castro-Hernández JR; González-Hernández T; Rodríguez M; Castro R
    Histol Histopathol; 2013 Aug; 28(8):999-1006. PubMed ID: 23444197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.
    Richter F; Gao F; Medvedeva V; Lee P; Bove N; Fleming SM; Michaud M; Lemesre V; Patassini S; De La Rosa K; Mulligan CK; Sioshansi PC; Zhu C; Coppola G; Bordet T; Pruss RM; Chesselet MF
    Neurobiol Dis; 2014 Sep; 69():263-75. PubMed ID: 24844147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rebamipide Mitigates Impairments in Mitochondrial Function and Bioenergetics with α-Synuclein Pathology in 6-OHDA-Induced Hemiparkinson's Model in Rats.
    Mishra A; Krishnamurthy S
    Neurotox Res; 2019 Apr; 35(3):542-562. PubMed ID: 30610666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration.
    Jimenez-Ferrer I; Jewett M; Tontanahal A; Romero-Ramos M; Swanberg M
    Neurobiol Dis; 2017 Oct; 106():279-290. PubMed ID: 28736195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.
    Finkelstein DI; Billings JL; Adlard PA; Ayton S; Sedjahtera A; Masters CL; Wilkins S; Shackleford DM; Charman SA; Bal W; Zawisza IA; Kurowska E; Gundlach AL; Ma S; Bush AI; Hare DJ; Doble PA; Crawford S; Gautier EC; Parsons J; Huggins P; Barnham KJ; Cherny RA
    Acta Neuropathol Commun; 2017 Jun; 5(1):53. PubMed ID: 28659169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
    Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease pathology is directly correlated to SIRT3 in human subjects and animal models: Implications for AAV.SIRT3-myc as a disease-modifying therapy.
    Trinh D; Israwi AR; Brar H; Villafuerte JEA; Laylo R; Patel H; Jafri S; Al Halabi L; Sinnathurai S; Reehal K; Shi A; Gnanamanogaran V; Garabedian N; Pham I; Thrasher D; Monnier PP; Volpicelli-Daley LA; Nash JE
    Neurobiol Dis; 2023 Oct; 187():106287. PubMed ID: 37704058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
    St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ
    J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Over-expression of the Sirt3 sirtuin Protects neuronally differentiated PC12 Cells from degeneration induced by oxidative stress and trophic withdrawal.
    Shulyakova N; Sidorova-Darmos E; Fong J; Zhang G; Mills LR; Eubanks JH
    Brain Res; 2014 Oct; 1587():40-53. PubMed ID: 25194924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.